Infectious Diseases News Round-Up

August 2009
PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p21
Market Research Report
The article offers world news briefs related to the pharmaceutical industry. Baxter International Inc. is developing an A/H1N1 vaccine using its Vero cell culture technology to respond the outbreak of H1N1 influenza. Novartis AG has received requests from over 30 governments for the delivery of its influenza vaccine ingredients. NexMed Inc. has decided to end its licensing agreement with Novartis AG for NM100060, a topically-applied treatment for onychomycosis.


Related Articles

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • Deals roundup.  // Medical Device Daily;7/9/2009, Vol. 13 Issue 130, p3 

    The article reports on the mutual decision of NexMed and Novartis to terminate their licensing agreement for NM100060, a topically-applied treatment for nail fungus. The licensing agreement was completed by the companies in September 2008. According to NexMed, the results of two Phase III...

  • NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product.  // Equities;Apr2007, Vol. 55 Issue 2, p124 

    The article reports on the start of patient dosing in the Phase 3 clinical trials for NM100060 anti-fungal treatment of Novartis according to NexMed Inc. which signed a licensing agreement with the pharmaceutical firm. It states that two pivotal, randomized, double-blind and placebo-controlled...

  • NexMed's U.S. patent triggers a milestone payment from Novartis.  // Medical Device Daily;10/29/2008, Vol. 12 Issue 211, p8 

    The article reports that the U.S. Patent & Trademark Office has issued a notice of allowance for NexMed's U.S. patent application titled, "Antifungal Nail Coat and Method of Use." The patent covers NM100060, a topical application of terbinafine formulated with NexACT for the treatment of...

  • NEWS BRIEFS.  // MondayMorning;1/19/2009, Vol. 17 Issue 2, p5 

    The article offers U.S. news briefs related to pharmaceutical industry. Colorado Senators on Friday approved a resolution asking Congress to reauthorize a program that helps states provide health insurance to needy children. The U.S. government has awarded Novartis AG a contract worth up to $486...

  • Novartis Paying $20M Up Front for CMV Candidate.  // Bioworld Week;1/5/2009, Vol. 17 Issue 1, p2 

    The article reports that AlphaVax Inc. has agreed to license rights to its Phase I-stage cytomegalovirus (CMV) vaccine program to Novartis AG in exchange of $20 million up-front payment. According to the term, AlphaVax Inc. will finalize trials for the vaccine candidate while Novartis AG will...

  • COMPANY SPOTLIGHT -- MedImmune.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p37 

    The article reports that MedImmune Inc. has licensed its reverse genetics technology to Novartis AG to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines. Reverse genetics is a method by which...

  • Drug makers scramble to create swine flu vaccine. DeArment, Alaric // Drug Store News;5/25/2009, Vol. 31 Issue 6, p4 

    The article reports on the growth of drug companies developing vaccines for the treatment of H1N1 influenza in the U.S. It reveals that Baxter International Inc. plans to develop Celvapan with the strain of A/H1N1, meanwhile, biotechnology company Novavax Inc. will create vaccines that will...

  • NEXMED LICENSES FEMPROX TO CJ CORP. FOR SOUTH KOREA.  // Worldwide Biotech;Apr2004, Vol. 16 Issue 4, p1 

    Reports that Femprox, a proprietary cream treatment for female sexual arousal disorder by NexMed, Inc., has been licensed by CJ Corp. for Korea. Terms of the agreement; Views of Hong-Chang Kim, president of Seoul, Korea-based CJ Pharmaceuticals, on their collaboration with NexMed; Background of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics